COMP <GO>
KYMR vs ABBV // GROSS PROFIT MARGIN
Kymera Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: KYMR 4
— ABBV 10
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $126.63 (+3.29%) • MKT CAP: $10.19B
gross-margins
0.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 0.00% | 70.20% | -70.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 29.00% | -50.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 3.47% | -5.77 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 6.90% | +61.10 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 8.60% | -25.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | KYMR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.3 | 72.8 | -3.45 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 113.1x | -82.70 | KYMR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $513.86B | -$503.67B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | ABBV REV | KYMR GROSS % | ABBV GROSS % | KYMR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $61.16B | 0.0% | 70.2% | -$234.3M | $17.82B |
| FY 2024 | $47.1M | $56.33B | 0.0% | 70.0% | -$207.3M | $17.83B |
| FY 2023 | $78.6M | $54.32B | 44.0% | 44.0% | -$106.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
ABBV // BETA 1.15